About US
Contact us
-
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall throughHalozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New J2025/4/17
-
Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPDAs Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary2025/4/17
-
Roche moves to mitigate US tariff impact amid discussions with global governmentsRoche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying to r2025/4/15
-
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctiveSchizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive treatment2025/4/15
-
Lilly files lawsuit against home town spa for selling repackaged ZepboundTo what extent will health clinics go to keep selling in-demand weight loss drugs now that the FDA has outlawed cheaper compounded versions of the branded treatments? According to a lawsuit filed by2025/4/10
-
Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug XyremAhead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. Early this week, th2025/4/10
-
Sun Pharma snags appeals win over Incyte, clearing way for US launch of alopecia med LeqselviAfter a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with riv2025/4/8
-
Rhythm eyes label expansion after Imcivree helps patients with brain damage-related obesity lose weightWhile pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking to corner a subset of the market with its Imcivree. About 5,000 to 10,0002025/4/8
-
CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy developmentOn the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decis2025/4/3
-
Novo’s Wegovy, J&J’s Tremfya step up TV ad spending amid March Madness tournamentLast year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds totake the full-year titlefor the thi2025/4/3